Overcoming docetaxel resistance in prostate cancer: a perspective review.
Overcoming docetaxel resistance in prostate cancer: a perspective review.
复制标题
DOI：
10.1177/1758834012449685
复制
发表时间：
2012-11
影响因子：
4.9
通讯作者：
Hwang C
中科院分区：
文献类型：
--
作者：
Hwang C
转移性去势抵抗性前列腺癌的治疗历来充满挑战，几乎没有取得成功。多西紫杉醇是第一种与去势抵抗性前列腺癌生存获益相关的细胞毒性疗法。毒性是其他细胞毒性药物的典型毒性，其中骨髓抑制是剂量限制性毒性，而神经毒性也是一些患者的显着副作用。不幸的是，很大一部分患有去势抵抗性前列腺癌的男性对多西紫杉醇治疗没有反应，所有患者最终都会产生耐药性。由于多西紫杉醇是一种有效的疗法，因此在可预见的将来，尽管它具有毒性和局限性，但它可能仍然是转移性前列腺癌治疗方法的重要组成部分。自从多西紫杉醇首次被确立为转移性去势抵抗性前列腺癌的一线疗法以来，克服多西紫杉醇耐药性一直是一个挑战。最近的研究表明，包括卡巴他赛和阿比特龙在内的几种新药在多西他赛失败后仍然有效，极大地改变了这些患者的治疗前景。此外，对多西紫杉醇耐药机制的更深入了解催生了几种新的治疗方法，这些方法对未来有希望。本综述将讨论转移性去势抵抗性前列腺癌的最新治疗进展以及正在进行的临床试验。
The treatment of metastatic castrate-resistant prostate cancer has been historically challenging, with few therapeutic successes. Docetaxel was the first cytotoxic therapy associated with a survival benefit in castrate-resistant prostate cancer. Toxicity is typical of other cytotoxic agents, with myelosuppression being the dose-limiting toxicity and neurotoxicity also a notable side effect for some patients. Unfortunately, a significant proportion of men with castrate-resistant prostate cancer will not respond to docetaxel-based therapy and all patients will ultimately develop resistance. Because it is an effective therapy, docetaxel is likely to remain an important part of the treatment arsenal against metastatic prostate cancer for the foreseeable future, despite its toxicities and limitations. Overcoming docetaxel resistance has been a challenge since docetaxel was first established as front-line therapy for metastatic castrate-resistant prostate cancer. Recent studies have shown that several new drugs, including cabazitaxel and abiraterone, are effective after docetaxel failure, dramatically changing the therapeutic landscape for these patients. In addition, a greater understanding of the mechanisms underlying docetaxel resistance has led to several new treatment approaches which hold promise for the future. This review will discuss recent therapeutic advances in metastatic castrate-resistant prostate cancer as well as ongoing clinical trials.
登录
查看更多内容
影响因子：
4.5
作者：
Gardner ER;Ahlers CM;Shukla S;Sissung TM;Ockers SB;Price DK;Hamada A;Robey RW;Steinberg SM;Ambudkar SV;Dahut WL;Figg WD
通讯作者：
Figg WD
影响因子：
2.8
作者：
Ho, Lye Lin;Kench, James G.;Horvath, Lisa G.
通讯作者：
Horvath, Lisa G.
DOI：
10.1056/nejmoa1014618
发表时间：
2011-05-26
期刊：
The New England journal of medicine
影响因子：
--
作者：
de Bono JS;Logothetis CJ;Molina A;Fizazi K;North S;Chu L;Chi KN;Jones RJ;Goodman OB Jr;Saad F;Staffurth JN;Mainwaring P;Harland S;Flaig TW;Hutson TE;Cheng T;Patterson H;Hainsworth JD;Ryan CJ;Sternberg CN;Ellard SL;Fléchon A;Saleh M;Scholz M;Efstathiou E;Zivi A;Bianchini D;Loriot Y;Chieffo N;Kheoh T;Haqq CM;Scher HI;COU-AA-301 Investigators
通讯作者：
COU-AA-301 Investigators
影响因子：
6.6
作者：
Berry, W;Dakhil, S;Asmar, L
通讯作者：
Asmar, L
影响因子：
45.3
作者：
Berthold, Dominik R.;Pond, Gregory R.;Tannock, Ian F.
通讯作者：
Tannock, Ian F.